Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has emerged to cause
pandemic respiratory disease in the past 2 years, leading to significant worldwide morbidity …

The current pandemic due to the SARS-CoV-2 virus has caused irreparable damage
globally. High importance is placed on defining current therapeutics for Coronavirus …

ABSTRACT Introduction Neutralizing antibodies (NAbs) that target key domains of the spike
protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have …

Background The effects of molnupiravir in treating patients with non-severe COVID-19
remain uncertain. Objectives To evaluate the efficacy and safety of molnupiravir in adult …

Background The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …

Introduction There are currently some differences in the research results of molnupiravir.
This study aimed to evaluate the efficacy and safety of molnupiravir in the treatment of …

Nucleoside analogs are a major class of antiviral drugs. Some act by increasing the viral
mutation rate causing lethal mutagenesis of the virus. Their mutagenic capacity, however …

An updated version of this article was published on 19 September 2023. This article has
been corrected. The original version of the article and supplement (PDF) is appended to this …

On 1 October 2021 Merck issued a press release 1 reporting an interim analysis of Move-
Out, a phase 3 randomised placebo controlled trial in unvaccinated adults with confirmed …

The efficacy of molnupiravir in treating patients with coronavirus disease 2019 (COVID‐19)
has been inconsistent across randomized controlled trials (RCTs). Thus, this meta‐analysis …